PTT Invests in Lotus Pharmaceutical's Strategic Partnership in South East Asia
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Robert Wessman, Chairman of Lotus Pharmaceuticals, commented: "This partnership is an important milestone in realizing our vision to establish Lotus as a global leader in generic oral oncology products. Lotus has secured partnerships with many of the leading pharmaceutical companies around the world to market and commercialize our products. The addition of Innobic (Asia) as a shareholder, will further support the long-term growth of Lotus in Asia and its mission to become a global leader in oral oncology."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
TAIPEI, Taiwan -- Businesswire -- Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be acquired by Innobic (Asia). The move is aimed at further strengthening the company’s market access in the ASEAN region. Innobic (Asia) is a wholly owned subsidiary of PTT Public Company Limited (“PTT”, SET ticker: PTT), the largest publicly listed conglomerate in Thailand. PTT, whose majority owner is the Ministry of Finance in Thailand, is the nation's only company listed in the Fortune Global 500.
Under the agreement, Innobic (Asia), PTT's Pharmaceutical and Life Science arm, commits to an investment of approximately US$50 million, to subscribe 17,517,348 new shares via private placement at the price of NT$80.7 per share.
Through this strategic alliance, Lotus and Innobic (Asia) will jointly explore opportunities in the South East Asia pharmaceutical markets, including but not limited to Thailand, Vietnam, Philippines, Malaysia and other ASEAN countries. The partnership combines Lotus’ strong pipeline, wide portfolio, R&D and Business Development capabilities, combined with extensive industry knowledge and high Good Manufacturing Practices (GMP) standards, with Innobic and PTT’s solid market access, local knowledge, creditability, potential commercial network and business relationship.
Robert Wessman, Chairman of Lotus Pharmaceuticals, commented: “This partnership is an important milestone in realizing our vision to establish Lotus as a global leader in generic oral oncology products. Lotus has secured partnerships with many of the leading pharmaceutical companies around the world to market and commercialize our products. The addition of Innobic (Asia) as a shareholder, will further support the long-term growth of Lotus in Asia and its mission to become a global leader in oral oncology.”
Dr. Buranin Rattanasombat, Senior Executive Vice President PTT group and Chairman of Innobic (Asia), commented: “PTT Group has continuously expanded our business value-chain to satisfy the changing demands of a diversified and broader customer base. With the rising concern on the importance of healthcare eco-system, it has become a part of our Innobic (Asia)’s strategy to promote innovative medicines in Thailand and South East Asia to improve patient’s access to more affordable medicines with quality. Today’s venture marks yet another successful milestone towards this goal. We are delighted to be partner with Lotus who we trust as leader in the industry.”
About Lotus
Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company’s internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees, and shareholders alike. The company boasts a best-in-class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company’s direct markets, relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.
About Innobic (Asia)
Innobic (Asia) Company Limited, officially established on December 2020, aims to drive for concrete Life Science businesses for PTT Group with its vision as leading life science company in regional by bringing best science and enhancing quality of life.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005449/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Lotus Pharmaceutical Co., Ltd.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- K-POP 글로벌 오디션 프로젝트 ‘클릭더스타’ 최초의 페루 걸그룹 ‘블링원’ 데뷔 - 뉴스와이어
- 투썸플레이스, 여름 시즌 한정 복숭아 디저트&음료 론칭 - 뉴스와이어
- 경북창조경제혁신센터, 2024 경북 글로벌 패키지 성장지원사업 15개 사 선정 - 뉴스와이어
- 이구스, 폐그물을 활용한 플라스틱 자전거 생산으로 지속 가능성에 대한 의지 드러내 - 뉴스와이
- 한국레노버, 비즈니스 노트북 ‘레노버 V15’ 4세대 오픈마켓 판매 시작 - 뉴스와이어
- SK네트웍스, 지난해 사회적 가치 성과 5690억원 규모 창출 - 뉴스와이어
- 동아제약, 건강한 음주를 위한 ‘모닝케어 간솔루션 젤리스틱’ 출시 - 뉴스와이어
- 한화시스템 사내벤처 플렉셀 스페이스, 미국 우주 시장 두드린다 - 뉴스와이어
- 전 세계 소셜 앱 수익 전년 대비 19% 증가하며 사상 최고치 기록… 글로벌 소셜 앱 수익 1위는 틱
- QPS, 임상실험 및 세포 치료제 개발을 위한 신규 실험실 서비스 발표 - 뉴스와이어